Inpharma

Management of tuberculosis reviewed
pp. 2-2(1)

Antiviral HCV therapy: give drug users a fair go
pp. 3-3(1)

Is there a right time to update clinical guidelines?
pp. 3-3(1)

Swedish guidelines for the management of RSV infections
pp. 3-3(1)

Improving treatment of type 1 diabetes mellitus
pp. 4-4(1)

Slashed antitubercular drug prices bring hope
pp. 4-4(1)

Emergency oral contraception cost saving in Canada
pp. 4-4(1)

Mercaptopurine more cost effective than mesalazine in Crohn's disease
pp. 5-6(2)

Gatifloxacin a cost-effective alternative for CAP
pp. 6-6(1)

Atorvastatin `most cost-effective' statin in 2° CHD prevention?
pp. 6-6(1)

Khellin + UVA therapy induces repigmentation in vitiligo
pp. 7-7(1)

Irregular medication use is a strong predictor of hospitalisation and associated costs
pp. 7-7(1)

Anticonvulsant monotherapy commonly used in Denmark
pp. 7-7(1)

RO 237553 enhances the effects of doxorubicin and irradiation on breast cancer cells
pp. 7-7(1)

Paroxetine seems to improve facial acne in adults and adolescents being treated for depression
pp. 8-8(1)

NBI-34060 effectively induces sleep in patients with chronic primary insomnia
pp. 8-8(1)

D-002 shows efficacy in healing duodenal ulcers
pp. 8-8(1)

SPM 962 reduces levodopa requirements in PD
pp. 8-8(1)

Emerging insulin therapies for diabetes
pp. 9-10(2)

S-ketamine beneficial adjunct to ropivacaine epidural anaesthesia
pp. 10-10(1)

Miglitol is an effective adjunct to metformin
pp. 10-10(1)

Patient compliance not associated with antihypertensive response?
pp. 11-11(1)

High-dose ursodeoxycholic acid (UDCA) may be beneficial in primary sclerosing cholangitis
pp. 11-11(1)

Bexarotene effective in advanced CTCL
pp. 11-11(1)

Pergolide shows long-term efficacy in the treatment of patients with restless legs syndrome
pp. 11-11(1)

Heparin-exercise therapy may be beneficial in patients with myocardial ischaemia
pp. 11-11(1)

Prolong anticoagulant therapy for idiopathic DVT?
pp. 12-12(1)

Start somatropin earlier in Turner's syndrome
pp. 12-12(1)

Prolonged antiplatelet therapy reduces risk of late thrombosis
pp. 12-12(1)

Pamidronic acid provided `remarkable relief' from bone pain
pp. 14-14(1)

Somatropin administration was associated with healing of cutaneous ulcers in a child
pp. 14-14(1)

Rituximab may be an effective treatment for chronic and refractory cold haemagglutinin disease
pp. 14-14(1)

Bexarotene + cisplatin + vinorelbine promising in NSCLC
pp. 14-14(1)

Nefazodone in chronic daily headache prophylaxis
pp. 14-14(1)

Multidrug-resistant TB `a curable disease'
pp. 15-15(1)

Low-dose somatropin effective in malnourished elderly patients
pp. 15-15(1)

Famotidine is beneficial in paediatric patients with recurrent abdominal pain
pp. 15-15(1)

Predicting cytogenetic response to interferon therapy in CML
pp. 16-16(1)

IFN--2a for active ulcerative colitis?
pp. 16-16(1)

Ciclopirox 1% cream is an effective and well-tolerated treatment
pp. 16-16(1)

Interferon- appears to be an effective treatment for focal epithelial hyperplasia
pp. 16-16(1)

Imiquimod may be beneficial in the treatment of verrucae planae
pp. 16-16(1)

Imiquimod may represent a promising new treatment for actinic keratosis
pp. 17-17(1)

A 6-month triple-drug regimen can effectively eradicate prostatic tuberculosis
pp. 17-17(1)

Mitoxantrone is more effective than doxorubicin when used in a fortnightly regimen
pp. 17-17(1)

Bet on naltrexone for pathological gambling
pp. 17-17(1)

Tacrolimus `appears to be an effective treatment option in acute steroid refractory IBD
pp. 17-17(1)

Mirtazapine may have a more rapid onset of action than SSRIs
pp. 17-17(1)

Linezolid resistance has been reported in a Staphylococcus aureus clinical isolate
pp. 18-18(1)

Oral valaciclovir: comparable systemic exposure to IV aciclovir
pp. 18-18(1)

SSRIs: antiplatelet effects in coronary artery disease
pp. 18-18(1)

Losartan and enalapril: similar effects on PAI and tissue factor levels in AMI
pp. 18-18(1)

Analgesics not associated with renal dysfunction in men
pp. 19-19(1)

Fatal cardiomyopathy and myocarditis with clozapine
pp. 19-19(1)

NSAID news from the European Congress of Rheumatology
pp. 20-21(2)

Incidence of VT greater with third-, than with second-generation OCs
pp. 21-21(1)

Sigma Tau revises labelling for levocarnitine
pp. 21-21(1)

Thymalfasin [`Zadaxin'; SciClone] has received marketing approval in Mexico
pp. 22-22(1)

Tazobactam/piperacillin [`Tazocin'; Toyama] has been launched in Japan
pp. 22-22(1)

Thymalfasin [`Zadaxin'; SciClone] has been approved in the Philippines
pp. 22-22(1)

Market news from Canada
pp. 22-22(1)

Market news from the US
pp. 22-22(1)

Market news from the European Union
pp. 22-22(1)